Compare Amgen, Inc. (AMGN) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while GraniteShares 2x Long NVDA Daily ETF trades at $32. The key difference: Amgen, Inc. pays a 2.77% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | NVDL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $43.02 |
52-Week Low | $271.18 | $21.76 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $33.03, up 8.08% with a bullish technical signal. Recent stock splits (1:3 on June 25-26, 2026) reflect volatility management. The ETF has shown strong YTD performance (+12.66% as of June 8, 2026) but remains highly sensitive to NVIDIA's daily moves, evidenced by a 12% single-day drop on June 5, 2026. Technical indicators show bullish moving averages but neutral oscillators, with key resistance at $33.
Outlook: High-growth potential tied to NVIDIA's AI dominance, but leveraged structure amplifies risks. Daily resets can erode value during volatility, as seen in early 2025's 67% decline. Investors must weigh AI-driven upside against compounded losses in downtrends. Key risks include NVIDIA-specific volatility and broader semiconductor cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
